Merck & Co (MSD) has initiated the randomised MOBILIZE-1 Phase III trial to assess the immunogenicity, efficacy, and safety ...

Merck is establishing a program of clinical trials for V181, including conducting trials globally, in places where dengue is ...

Merck initiates MOBILIZE-1 phase 3 study evaluating dengue vaccine candidate, V181: Rahway, New Jersey Friday, June 13, 2025, 11:00 Hrs [IST] Merck, known as MSD outside of the Un ...

While Takeda's Qdenga (TAK-003) shot is approved as a two-dose regimen to protect people from the disease in dozens of ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 ...

Merck & Co Inc (NYSE:MRK) has begun a Phase 3 clinical trial to test its experimental dengue vaccine in a pediatric ...

Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. Non-Commercial (NC): Only non-commercial uses of the work are permitted.

在最新版本(v181)中，使用ollama本地部署的模型,在 ios 端和 web 端无法加载模型，然而 MacOs app 及 安卓设备中使用是可以的 ...

Scientific American is part of Springer Nature, which owns or has commercial relations with thousands of scientific publications (many of them can be found at www ...

Scientific American is part of Springer Nature, which owns or has commercial relations with thousands of scientific publications (many of them can be found at www ...

Laboratory of Environmental Chemistry, School of Architecture, Civil and Environmental Engineering (ENAC), École Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland ...

As the most lethal gynecologic oncological indication, carcinoma of the ovary has been ranked as the 5 th cause of cancer-related mortality in women, with a high percentage of the patients being ...